BREAKFAST SYMPOSIUM

Clinical and technical considerations for homologous recombination deficiency (HRD) testing in solid tumors

The homologous recombination repair (HRR) pathway is critical for maintaining genomic integrity and is a high-fidelity repair mechanism of DNA double‐strand breaks. Deficiencies in the HRR pathway, or HRD, have been observed across several tumor types including breast, ovarian, prostate, and pancreatic cancers. HRD is a phenotype characterized genomic instability, which can render tumors sensitive to platinum-based chemotherapy and PARP inhibitors. To identify patients with HRD-positive tumors, it is important to understand the current indications for HRD testing and how to best measure HRR status. In this presentation, we will review the clinical and technical considerations for HRD testing across applicable solid tumors.

Alison Roos, PhD,
Associate Director, Medical Affairs, Illumina Inc.

Alison Roos, PhD, is an associate director in oncology medical affairs at Illumina. She holds a PhD in molecular and cellular biology from the Baylor College of Medicine. Her academic career included research focused on understanding the role of genomics in sarcomas and pediatric and adult brain tumors. She also spent time as a scientist at the Translational Genomics Research Institute (TGen), where she worked on TGen's pediatric and adult oncology precision medicine studies. Alison has over 6-years of experience in molecular diagnostics space and has worked in Medical Affairs at somatic testing companies. Alison has a passion for developing and deploying medical education that highlights the value of genomics testing for pediatric and adult patients with solid tumors and hematologic malignancies.
Please connect: https://www.linkedin.com/in/alison-roos-b7919660/